ArticleLeukemia research reports2025

BCR::ABL1 kinase domain mutations and their predictive value for treatment outcomes in patients with chronic myeloid leukemia treated with first-line imatinib in a low-income setting: Experience from Côte d'Ivoire.

Kouassi Gustave Koffi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.